# ScoreItem: DHEA-S - Homens (50-59 anos)

**ID:** `019bf31d-2ef0-7dd6-ad03-6da22ffd7fea`
**FullName:** DHEA-S - Homens (50-59 anos) (Exames - Laboratoriais)
**Unit:** ¬µg/dL
**Gender:** male
**Age Min:** 50 anos
**Age Max:** 59 anos

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 11 artigos
- Avg Similarity: 0.665

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7dd6-ad03-6da22ffd7fea`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7dd6-ad03-6da22ffd7fea",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** DHEA-S - Homens (50-59 anos) (Exames - Laboratoriais)
**Unidade:** ¬µg/dL
**G√™nero:** male
**Faixa Et√°ria:** 50-59 anos

**30 chunks de 11 artigos (avg similarity: 0.665)**

### Chunk 1/30
**Article:** Dehydroepiandrosterone and its Sulfate Predict the 5-Year Risk of Coronary Heart Disease Events in Elderly Men (2014)
**Journal:** Journal of the American College of Cardiology
**Section:** abstract | **Similarity:** 0.711

Estudo prospectivo com 2.416 homens idosos (69-81 anos) seguidos por 5 anos demonstrou que n√≠veis s√©ricos baixos de DHEA e DHEA-S predizem risco aumentado de eventos de doen√ßa coronariana. Ambos DHEA e DHEA-S foram inversamente associados com risco ajustado por idade de evento coronariano (hazard ratios por SD de aumento: 0.82 e 0.86, respectivamente). Os n√≠veis baixos de DHEA-S foram particularmente preditivos em homens mais jovens dentro da coorte, sugerindo que a mensura√ß√£o de DHEA-S pode ter valor progn√≥stico cardiovascular em homens na quinta e sexta d√©cadas de vida.

---

### Chunk 2/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.693

composition with metabolism and disease. J Nutr Health Aging 2005;9:408‚Äì419
86. Berkman LF, Seeman TE, Albert M et al. High, usual and impaired functioning in
community-dwelling older men and women: Findings from the MacArthur Foundation
Research Network on Successful Aging. 
J Clin Epidemiol 1993;46:1129‚Äì1140
87. Morrison MF, Katz IR, Parmelee P et al. 
Dehydroepiandrosterone sulfate (DHEA-S) and
psychiatric and laboratory measures of frailty in a residential care population. Am J Geriatr
Psychiatry 1998;6:277‚Äì284
88. Abbasi A, Duthie EH, Sheldahl L et al. Association of dehydroepiandrosterone sulfate,
body composition, and physical fitness in independent communitydwelling older men and
women. J Am Geriatr Soc 1998;46:263‚Äì273
89. Clarke BL, Ebeling PR, Jones JD, Wahner HW, O‚ÄôFallon WM, Riggs BL, Fitzpatrick LA.
Predictors of bone mineraldensity in aging healthy men varies by skeletal site. Calcified Tiss
Int 2002;70:137‚Äì145
90.

---

### Chunk 3/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.691

n in the analysis. However, the potential inÔ¨Çuence of such metabolic factors on DHEA supplementation outcomes could introduce bias. Despite this, sensitivity analyses indicated that no single study disproportionately aÔ¨Äected the overall results, supporting the robustness of our conclusions.Our review did not account for these metabolic and comorbidity-related factors, which future research should control for or report in detail to minimize bias. Additionally, sensitivity analyses addressing these vari-ables would be valuable in future meta-analyses.Conclusionis meta-analysis found that DHEA supplementation at doses of 50 mg/day or higher signiÔ¨Åcantly increased testosterone levels, and in participants aged 60 years or older, signiÔ¨Åcantly elevated estradiol levels.

---

### Chunk 4/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.687

man  HA,  Johannes  CB,  Araujo  AB,  Mohr  BA,  Longcope  C,  McKinlay  JB.
Low dehydroepiandrosterone  and  ischemic  heart  disease  in  middle-aged  men:
prospective  results  from  the  Massachusetts  Male  Aging  Study.  Am  J  Epidemiol
2001;153:79‚Äì89
246. Trivedi  DP,  Khaw  KT.  Dehydroepiandrosterone  sulfate  and  mortality  in elderly
men  and  women.  J  Clin  Endocrinol  Metab  2001;86:4171‚Äì7
247. Hak  AE,  Witteman  JC,  de  Jong  FH,  Geerlings  MI,  Hofman  A,  Pols  HA.  Low
levels of  endogenous  androgens  increase  the  risk  of  atherosclerosis  in  elderly  men:
the  Rotterdam  study.  J  Clin  Endocrinol  Metab  2002;87:3632‚Äì9
248. Herrington  DM,  Gordon  GB,  Achuff  SC,  Trejo  JF,  Weisman  HF,  Kwiterovich  Jr
PO,  et  al.  Plasma  dehydroepiandrosterone  and  dehydroepiandrosterone  sulfate  in
patients  undergoing  diagnostic  coronary  angiography.  J  Am  Coll Cardiol  1990;16:862‚Äì
70
249.

---

### Chunk 5/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.683

208
]. In humans studies, however, the results  are
rather inconsistent. In some studies, the lower levels of DHEA seen with aging have been
associated with impaired glucose tolerance, insulin resistance and diabetes [
212
-
215
], while
in another [
216
] exactly the opposite relation was shown as higher levels of DHEA were
13

associated with impaired glucose tolerance and diabetes mellitus in post-menopausal
women. The truth regarding DHEA/DHEAS and insulin resistance and its associated
conditions gets even more complicated considering conflicting results from interventional
studies with DHEA replacement. Thus, an ameliorating effect of long-term treatment with
DHEA on insulin resistance was described in a group of middle-aged hypo-adrenal women
treated with DHEA [
217
], but also in groups of elderly men [
97
] and postmenopausal women
[
97,217-220
] replaced with DHEA.

---

### Chunk 6/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** results | **Similarity:** 0.681

was further supported by the results of Egger¬ís regression test.Discussionis meta-analysis of randomized controlled trials (RCTs) evaluated the eÔ¨Äects of dehydroepiandrosterone (DHEA) supplementation on testosterone and estradiol levels in postmenopausal women. Our analysis of 21 RCTs revealed that DHEA supplementation signiÔ¨Åcantly increased both testosterone and estradiol concentrations, although substantial heterogeneity was observed across the included trials.Our Ô¨Åndings indicate that DHEA is particularly eÔ¨Äec-tive in elevating testosterone levels when administered at dosages  50 mg/day. Additionally, a marked increase in estradiol levels was noted among participants aged  60 years receiving the same dosage. ese Ô¨Åndings 
Fig. 2 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig.

---

### Chunk 7/30
**Article:** Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men (2010)
**Journal:** Journal of Clinical Endocrinology and Metabolism
**Section:** abstract | **Similarity:** 0.681

Estudo prospectivo com 2.644 homens suecos idosos (69-81 anos) demonstrou que n√≠veis s√©ricos baixos de DHEA-S predizem mortalidade por todas as causas (HR 1.54), doen√ßa cardiovascular (HR 1.61) e doen√ßa card√≠aca isqu√™mica (HR 1.67). Notavelmente, a predi√ß√£o de mortalidade por DHEA-S baixo foi mais pronunciada em homens mais jovens (HR ajustado por idade para morte cardiovascular 2.64) comparado a homens mais velhos (HR 1.30). Estes achados sugerem que a mensura√ß√£o de DHEA-S em homens na quinta d√©cada pode identificar indiv√≠duos com risco cardiovascular aumentado.

---

### Chunk 8/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.679

men. Age Ageing 2009;38:401‚Äì406
70. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate,
and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Nat Acad Natl
Sci 2000;97:4279‚Äì84
71. Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, et al. Low serum
levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in
elderly Swedish men. J Clin Endocrinol Metab 2010; 95: 4406‚Äì4414
72. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF (1999) DHEA and DHEA-S: a
review. 
J Clin Pharmacol 39: 327‚Äì348
73. Nair KS, Rizza RA, O‚ÄôBrien P, et al. 
DHEA in elderly women and DHEA or testosterone
in elderly men. N Engl J Med 2006;355:1647‚Äì1659
74. William L. Baker, Shobha Karan, and Anne M. Kenny Effect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997‚Äì1002
75. Kritz-Silverstein D, von M√ºhlen D, Gail A.

---

### Chunk 9/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.677

Stanczyk FZ, Bairey Merz CN. DHEA-S levels and
cardiovascular disease mortality in postmenopausal women: Results from the National
Institutes of Health‚ÄìNational Heart, Lung, and Blood Institute (NHLBI)-sponsored Women‚Äôs
Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985‚Äì4992
204. Christiansen JJ, Andersen NH, S√∏rensen KE, Pedersen EM, Bennett P, Andersen M,
Christiansen JS, J√∏rgensen JO, Gravholt CH. Dehydroepiandrosterone substitution in
female adrenal failure: no impact on endothelial function and cardiovascular parameters
despite normalization of androgen status. Clin Endocrinol 2007;66:426‚Äì433
205. Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of
oral DHEA therapy for postmenopausal women. Maturitas 2009;63:240‚Äì245
206. Cleary MP, Zisk JF. Anti-obesity effect of two different levels of
dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes
1986;10:193‚Äì204
207.

---

### Chunk 10/30
**Article:** Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women (2025)
**Journal:** Clinical Endocrinology
**Section:** abstract | **Similarity:** 0.676

Diretriz cl√≠nica da Society for Endocrinology para avalia√ß√£o de excesso androg√™nico em mulheres. DHEA-S s√©rico √© a medida mais confi√°vel de produ√ß√£o adrenal de andr√≥genos, particularmente √∫til na transi√ß√£o perimenop√°usica. Aproximadamente 25% da produ√ß√£o androg√™nica ocorre nas adrenais em mulheres pr√©-menop√°usicas, aumentando para 100% na p√≥s-menopausa. Decl√≠nio de DHEA-S inicia aos 30 anos devido √† involu√ß√£o da zona reticular adrenal.

---

### Chunk 11/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.673

ement
in healthy men with age-related decline of DHEA-S: Effects on fat distribution, insulin
sensitivity and lipid metabolism. Aging Male 2003; 6:151‚Äì156
27

108. Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio
B. Dehydroepiandrosterone replacement in women with adrenal insufficiency: Effects on
body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol
Metab 2001;86:1968‚Äì 1972
109. Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G.
Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab
1999;84:1527‚Äì1533
110. Percheron G, Hogrel JY, Denot-Ledunois S, Fayet G, Forette F, Baulieu EE, Fardeau
M, Marini JF. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-
year-old individuals on muscle function and cross-sectional area: A double-blind placebo-
controlled trial. Arch Int Med 2003;163:720‚Äì727
111.

---

### Chunk 12/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.664

:4279‚Äì
84
21

18. Mazat  L,  Lafont  S,  Berr  C,  Debuire  B,  Tessier  JF,  Dartigues  JF,  et  al.
Prospective measurements  of  dehydroepiandrosterone  sulfate  in  a  cohort  of  elderly
subjects:  relationship  to  gender,  subjective  health,  smoking  habits,  and 10-year
mortality.  Proc  Natl  Acad  Sci  U  S  A  2001;98:8145‚Äì50
19. Heaney JL, Phillips AC, Carroll D. Ageing, physical function, and the diurnal rhythms of
cortisol and dehydroepiandrosterone.Psychoneuroendocrinology. 2012;37(3):341-9
20. Laughlin, G. A. and Barrett-Connor, E. Sexual dimorphism in the influence of advanced
aging on adrenal hormone levels: the Rancho Bernardo Study. J Clin Endocrinol Metab
2000;85:3561-3568
21. Baulieu  EE.  Androgens  and  aging  men.  Mol  Cell  Endocrinol  2002;198:41‚Äì9
22. 
Parker, C.R. Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in
the human adrenal during development and aging. Steriods 1999;64, 640‚Äî647
23. Yen, S.S.C., Laughlin, G.A.

---

### Chunk 13/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.663

80 anos com testosterona de 500-600, sugerindo que seus n√≠veis de pico na juventude poderiam ter sido muito mais altos (ex: 1.500).
*   **Decl√≠nio Hormonal Feminino e DHEA**
    - Mulheres tamb√©m experimentam um decl√≠nio na testosterona, que √© produzida pelos ov√°rios e adrenais. A queda pode ser menos linear que nos homens, pois a produ√ß√£o adrenal pode ser preservada.
    - O DHEA (deidroepiandrosterona), um pr√≥-horm√¥nio precursor, diminui nitidamente com a idade, indicando um "desgaste" da gl√¢ndula adrenal.
    - A prescri√ß√£o de DHEA (prasterona no Brasil) √© feita em comprimidos (forma mais estudada) ou creme (forma mais fisiol√≥gica). Doses para mulheres s√£o menores (10-15mg) para evitar convers√µes indesejadas. Para homens, sua fun√ß√£o como estimulador de outros horm√¥nios √© menos estabelecida.
### 4.

---

### Chunk 14/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** introduction | **Similarity:** 0.660

lasma levels of adrenal androgens and CVD. Most have shown that low
plasma levels of  DHEA/DHEA-S  were clearly associated with increased incidence of
atherosclerotic vascular diseases [239-243] and cardiovascular morbidity [241,244-250],
independently from classic cardiovascular risk factors, as well as with increased CVD-related
mortality in elderly men [18,71,251-253] but not in postmenopausal women [18,246,251-
253], unless they had pre-existing coronary disease [203]. 
The plasma levels of DHEA were also inversely associated with the progression [254] and
prognosis of heart failure [255], at least in men. The exact pathophysiologic background is
still more or less unclear. Some preliminary data in patients with type 2 diabetes mellitus
suggest that the adrenal androgens may increase the generation of activated protein C, an
important anticoagulant protein that protects from acute 
coronary
 events [235].

---

### Chunk 15/30
**Article:** Low serum dehydroepiandrosterone is associated with diabetic dyslipidemia risk in males with type 2 diabetes (2023)
**Journal:** Frontiers in Endocrinology
**Section:** abstract | **Similarity:** 0.659

Estudo demonstrou associa√ß√£o entre baixos n√≠veis s√©ricos de DHEA e risco aumentado de dislipidemia diab√©tica em homens com diabetes tipo 2. A defici√™ncia de DHEA pode representar um fator de risco cardiovascular adicional em homens diab√©ticos de meia-idade, destacando a import√¢ncia da monitoriza√ß√£o deste horm√¥nio nesta popula√ß√£o.

---

### Chunk 16/30
**Article:** Dehydroepiandrosterone Supplementation in Elderly Men: A Meta-Analysis Study of Placebo-Controlled Trials (2013)
**Journal:** The Journal of Clinical Endocrinology & Metabolism
**Section:** abstract | **Similarity:** 0.659

Meta-an√°lise de ensaios cl√≠nicos randomizados controlados por placebo avaliando suplementa√ß√£o de DHEA em homens idosos. Os resultados n√£o demonstraram efeito da suplementa√ß√£o de DHEA em compara√ß√£o com placebo para diversos par√¢metros cl√≠nicos incluindo metabolismo lip√≠dico e glic√™mico, sa√∫de √≥ssea, fun√ß√£o sexual e qualidade de vida. A suplementa√ß√£o foi associada √† redu√ß√£o da massa gorda, por√©m este efeito depende estritamente da convers√£o do DHEA em metab√≥litos bioativos como andr√≥genos ou estrog√™nios.

---

### Chunk 17/30
**Article:** A Review of Age-Related Dehydroepiandrosterone Decline and Its Association with Well-Known Geriatric Syndromes: Is Treatment Beneficial? (2013)
**Journal:** Rejuvenation Research
**Section:** abstract | **Similarity:** 0.656

Revis√£o abrangente sobre o decl√≠nio de DHEA relacionado √† idade e associa√ß√µes com s√≠ndromes geri√°tricas. N√≠veis de DHEA variam entre 1,33-7,78 ng/mL entre 18-40 anos, declinando para 10-20% desses valores aos 70-80 anos. Associa√ß√µes prim√°rias incluem deteriora√ß√£o musculoesquel√©tica (for√ßa muscular, densidade √≥ssea), decl√≠nio cognitivo, transtornos de humor e risco cardiovascular.

---

### Chunk 18/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 03 (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.656

vida.
   - Em materiais did√°ticos do Dr. Merwin/Morgan Taylor, resultados foram apresentados como sem aumento de risco (‚Äúharmful zero‚Äù) e com benef√≠cios gerais na reposi√ß√£o quando bem indicada.
* Preven√ß√£o vs tratamento agudo
   - A testosterona n√£o ‚Äúsalva‚Äù no evento agudo (infarto), mas pode ter papel preventivo ao melhorar fatores de risco e estado geral (ex.: composi√ß√£o corporal, energia, bem-estar).
### 4. Avalia√ß√£o cl√≠nica e question√°rios
* Ferramentas de triagem
   - Question√°rios citados: St. Louis University (ADAM), AMS, MMAS, HRS. Podem ser baixados, mas o instrutor considera desnecess√°rios como √∫nico crit√©rio, devido √† ampla inespecificidade dos sintomas.
* Sintomas e sinais de baixa testosterona
   - Homens: irritabilidade, fadiga, baixa libido, diminui√ß√£o de pelos nas pernas, depress√£o, sarcopenia, aumento de gordura (principalmente abdominal), ins√¥nia, disfun√ß√£o er√©til.

---

### Chunk 19/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.655

rt (28 days), and the DHEA dosage supraphysiological (1600
mg/day 
per os
). Puting together the above, the relation between DHEA and carbohydrate
metabolism is still uncertain.
3g. DHEA & cardiovascular disease (CVD)
CVD represents a serious public health problem; its prevalence increases with advancing
age [
225
]. Low androgen levels have been related to atherogenic profile in men [
226
,
227
],
while data from acute coronary units have shown transient fall of the testosterone levels in
the first 24 hours after myocardial infarction (MI) [
228
,
229
], which probably deprives these
patients of  testosterone‚Äôs pro-fibrinolytic activity [
230
-
232
] and may actually result in
increased 30-day mortality rate following acute MI [
233
]; the above findings suggest a strong
relation between sex steroid hormones and CVD morbidity and mortality.

---

### Chunk 20/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** discussion | **Similarity:** 0.654

ffect of Dehydroepiandrosterone
on Muscle Strength and Physical Function in Older Adults: A Systematic Review. J Am
Geriatr Soc 2011;59:997‚Äì1002
75. Kritz-Silverstein D, von M√ºhlen D, Gail A. Laughlin GA, Bettencourt R. Effects of
dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA
and well-ness (DAWN) trial. J Am Geriat Soc 2008;56:1292‚Äì8
76. Panjari M, Bell RJ, Jane F, et al..A randomized trial of oral DHEA treatment for sexual
function, well-being, and menopausal symptoms in postmenopausal women with low libido. J
Sex Med 2009; 6: 2579‚Äì2590
77. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and metaanalysis of
randomized placebo-controlled trials of DHEA treatment effects on quality of life in women
with adrenal insufficiency.
J Clin Endocrinol Metab 2009;94:3676‚Äì81
78. Labrie F, Archer D, Bouchard C, et al.

---

### Chunk 21/30
**Article:** MFI - Reposi√ß√£o Hormonal - AULA 01 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.653

reavaliar a cada 6‚Äì8 semanas, checar SHBG, estradiol, DHT se pertinente) para padronizar seguimento.
### 8. DHEA (prasterona): papel, prescri√ß√£o e diferen√ßas entre sexos
- DHEA/DHEA-S: pr√≥-horm√¥nio, n√£o considerado horm√¥nio pleno; decl√≠nio com a idade, especialmente adrenal.
- Em mulheres, pode estimular horm√¥nios subsequentes; em homens, n√£o costuma ter fun√ß√£o robusta para estimular outros horm√¥nios.
- No Brasil, prescri√ß√£o como prasterona; estudos principalmente com comprimido; creme seria mais fisiol√≥gico, por√©m menos estudado; ambas formas poss√≠veis.
- Doses mulheres: baixas (10‚Äì15 mg) e monitorar porque pode elevar horm√¥nios indesejados; utilidade em infertilidade/autoimunes com dose b√°sica.
- Conceito de ‚Äúdesgaste‚Äù glandular ao longo da vida aplic√°vel √†s adrenais.
> **Sugest√µes de IA**
> - Organiza√ß√£o: Voc√™ delimitou bem diferen√ßas por sexo; inclua crit√©rios claros de quando considerar prasterona (indica√ß√µes vs quando evitar).

---

### Chunk 22/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.652

sterone (DHEA) and its active metabolite DHEA sulfate (DHEAS), are
steroid hormones synthesized and excreted primarily by the 
zona reticularis
 of the adrenal
cortex in response to adrenocorticotropic hormone (ACTH). They exert weak androgenic
effects and are therefore considered precursor hormones that need to be transformed to
potent androgens or estrogens to exert their effects. The potential clinical roles of
DHEA/DHEAS have been studied extensively, as previous epidemiologic and prospective
studies associated the age-related decrease of DHEA/DHEAS levels with higher prevalence
of degenerative disorders and increased frailty and mortality from all causes in the elderly,
attributing to adrenal androgens anti-ageing properties. But do they really suggest that they
are hormones related to longevity or just another pointless alchemy against ageing?

---

### Chunk 23/30
**Article:** Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.651

st. 2007;
2007:73754. doi:10.1155/2007/73754
11. Wu FCW, Tajar A, Beynon JM, et al; EMAS Group.
Identification of late-onset hypogonadism in
middle-aged and elderly men. N Engl J Med. 2010;
363(2):123-135. doi:10.1056/NEJMoa0911101
12. Feldman HA, Longcope C, Derby CA, et al.
Age trends in the level of serum testosterone and
other hormones in middle-aged men: longitudinal
results from the Massachusetts Male Aging Study.
J Clin Endocrinol Metab. 2002;87(2):589-598.
doi:10.1210/jcem.87.2.8201
13. Walther A, Ehlert U. Steroid secretion and
psychological well-being in men 40+. In: Rice T,
Sher L, eds. Neurobiology of Men‚Äôs Mental Health.
New York, NY: Nova; 2015:287-322.
14. Walther A, Philipp M, Lozza N, Ehlert U.
The rate of change in declining steroid hormones:
a new parameter of healthy aging in men?
Oncotarget. 2016;7(38):60844-60857. doi:10.18632
/oncotarget.11752

Original Investigation Research

25. Shores MM, Sloan KL, Matsumoto AM, Moceri
VM, Felker B, Kivlahan DR.

---

### Chunk 24/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.651

dose dehydroepiandrosterone affects
behavior in hypopituitary androgen-deficient women: a placebocontrolled trial. J Clin
Endocrinol Metab 2002;87:2046
144. van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione,
superimposed on growth hormone substitution, on quality of life and insulin-like growth factor
I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-
over trial. J Clin Endocrinol Metab 2005;90:3295‚Äì303
145. Lovas K, Gebre-Medhin G, Trovik T, et al. Replacement of dehydroepiandrosterone in
adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized
parallel group clinical trial. J Clin Endocrinol Metab 2003;88:1112‚Äì8
146. Avis NE, Brockwell S, Randolph Jr JF, et al. Longitudinal changes in sexual functioning
as women transition through menopause: results from the Study of Women‚Äôs Health Across
the Nation. Menopause 2009;16:442‚Äì52
147.

---

### Chunk 25/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.650

ials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum estradiol concentrations

Page 9 of 13
Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
Fig. 3 Forest plot of the randomized controlled trials investigating the eÔ¨Äect of dehydroepiandrosterone (DHEA) supplementation on serum testosterone concentrations
Fig. 4 Funnel plot of the weighted mean diÔ¨Äerence (WMD) versus the standard error (s.e.) of the WMD

Page 10 of 13Heetal. Diabetology & Metabolic Syndrome          (2025) 17:258 
are consistent with a previous meta-analysis by Li etal., which reported increased testosterone levels in partici-pants receiving > 50 mg/day of DHEA for  12 weeks, particularly among those under 60 years of age [40]. Sim-ilarly, Zhu etal. found that estradiol concentrations were signiÔ¨Åcantly increased in participants aged  60 years who received  50 mg/day of DHEA for  26 weeks [41].

---

### Chunk 26/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.650

000, Shandong Province, China. 3 Depart-ment of Internal Medicine, Man-Zhuang Town Hospital, District Daiyue, Tai¬ían City 271024, Shandong Province, China. Received: 8 May 2025   Accepted: 30 May 2025
References 1. Nenezic N, Kostic S, Strac DS, Grunauer M, Nenezic D, Radosav-ljevic M, et al. Dehydroepiandrosterone (DHEA): pharmacological eÔ¨Äects and potential therapeutic application. Mini Rev Med Chem. 2023;23(8):941¬ñ52. 2. Chen H, Jin Z, Sun C, Santos HO, KordVarkaneh H. EÔ¨Äects of dehydroe-piandrosterone (DHEA) supplementation on cortisol, leptin, adiponec-tin, and liver enzyme levels: a systematic review and meta-analysis of randomised clinical trials. Int J Clin Pract. 2021;75(11):e14698. 3. Xie M, Zhong Y, Xue Q, Wu M, Deng X, Santos HO, et al. Impact of dehy-droepianrosterone (DHEA) supplementation on serum levels of insulin-like growth factor 1 (IGF-1): a dose-response meta-analysis of randomized controlled trials. Exp Gerontol. 2020;136:110949. 4.

---

### Chunk 27/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** results | **Similarity:** 0.649

n sex steroid hormones and CVD morbidity and mortality. Many studies have
previously documented significant inverse relations between low DHEA/DHEAS levels and
key elements involved in the development of atherosclerosis and CVD, including carotid
artery intima-media thickness (IMT) [
234
,
235
], oxidative stress [
58
-
61
] and endothelial
dysfunction [
236
], independent of other coronary risk factors. Low DHEAS levels were also
predictive of severe coronary atherosclerosis on coronary angiography [
237
], but also of
earlier cardiac allograft vasculopathy development in heart transplant patients [
238
]. 
These findings are suggestive of anti-atherogenic and cardioprotective effect of
DHEA/DHEAS. Numerous epidemiological studies have, therefore, looked at the specific
relation between plasma levels of adrenal androgens and CVD.

---

### Chunk 28/30
**Article:** Adrenal Androgens and Aging (2023)
**Journal:** Endotext
**Section:** other | **Similarity:** 0.647

-I and testosterone in
healthy active elderly people. Eur J Appl Physiol 2000;82:83‚Äì90
67. Ravaglia G, Forti P, Maioli F, Boschi F, Cicognani A, Bernardi M, Pratelli L, Pizzoferrato
A, Porcu S, Gasbarrini G. Determinants of functional status in healthy Italian nonagenarians
and centenarians: A comprehensive functional assessment by the instruments of geriatric
practice. J Am Geriatr Soc 1997;45:1196‚Äì1202
68. Leng SX, Cappola AR, Anderson RE et al. Serum levels of insulin-like growth factor-I
(IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum
interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 2004;16:153‚Äì157
69. Voznesensky M, Walsh S, Dauser D et al. The association between
dehydroepiandosterone and frailty in older men and women. Age Ageing 2009;38:401‚Äì406
70. Baulieu E, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate,
and aging: contribution of the DHEAge study to a sociobiomedical issue.

---

### Chunk 29/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.646

HEA) supplementation on serum levels of insulin-like growth factor 1 (IGF-1): a dose-response meta-analysis of randomized controlled trials. Exp Gerontol. 2020;136:110949. 4. Mohamad N-V, Razali N-SC, Shamsuddin N-AM. Dehydroepiandros-terone and bone health: mechanisms and insights. Biomedicines. 2024;12(12):2780. 5. Mueller JW, Gilligan LC, Idkowiak J, Arlt W, Foster PA. The regula-tion of steroid action by sulfation and desulfation. Endocr Rev. 2015;36(5):526¬ñ63. 6. Tang J, Chen L-R, Chen K-H. The utilization of dehydroepiandrosterone as a sexual hormone precursor in premenopausal and postmenopausal women: an overview. Pharmaceuticals. 2021;15(1):46. 7. Yang N-C, Jeng K-CG, Ho W-M, Chou S-J, Hu M-L. DHEA inhibits cell growth and induces apoptosis in BV-2 cells and the eÔ¨Äects are inversely associated with glucose concentration in the medium. J Steroid Biochem Mol Biol. 2000;75(2¬ñ3):159¬ñ66. 8. De Menezes KJ, Peixoto C, Nardi AE, Carta MG, Machado S, Veras AB.

---

### Chunk 30/30
**Article:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects (2025)
**Journal:** Diabetology & Metabolic Syndrome
**Section:** discussion | **Similarity:** 0.646

/ doi. org/ 10. 1046/j. 1365- 2265. 1998. 00507.x. 38. Kudielka BM, Hellhammer J, Hellhammer DH, Wolf OT, Pirke KM, Varadi E, et al. Sex diÔ¨Äerences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998;83(5):1756¬ñ61. https:// doi. org/ 10. 1210/ jcem. 83.5. 4758. 39. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abra-ham GE, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995;63(5):1027¬ñ31. 40. Li Y, Ren J, Li N, Liu J, Tan SC, Low TY, et al. A dose-response and meta-analysis of dehydroepiandrosterone (DHEA) supplementation on testosterone levels: perinatal prediction of randomized clinical trials. Exp Gerontol. 2020;141: 111110. 41. Zhu Y, Qiu L, Jiang F, GƒÉman M-A, Abudoraehem OS, Okunade KS, et al.

---

